The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Aliev N.A.

Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare Department, Moscow, Russia

Aliev Z.N.

Clinical characteristics and treatment of depersonalization disorders

Authors:

Aliev N.A., Aliev Z.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(6): 97‑101

Read: 15255 times

Download PDF (RU)
Contact the author
Table of contents

CLINICAL CHARACTERISTICS AND TREATMENT OF DEPERSONALIZATION DISORDERS
CLINICAL CHARACTERISTICS AND TREATMENT OF DEPERSONALIZATION DISORDERS

To cite this article:

Aliev NA, Aliev ZN. Clinical characteristics and treatment of depersonalization disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(6):97‑101. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Combined treatment of patients with acute muscular tonic syndrome with dorsopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):70-77
Stress and sleep: Neurobiological aspe­cts and modern options of inso­mnia therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):14-21
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Early diagnosis and effe­ctive therapy of diabetic poly­neuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):62-68
Characteristics, treatment features and in-hospital mortality of patients with myocardial infa­rction over 75 years old in Russia acco­rding to the REGION-IM regi­stry. Russian Cardiology Bulletin. 2025;(1):22-38
Pharmacological treatment and prevention of ischemia-reperfusion syndrome in percutaneous coro­nary inte­rvention. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):191-200
Influence of griseofulvin on inte­stinal microbiota in the treatment of microsporia in rural children. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):185-190
Postoperative peri­tonitis: epidemiology, diagnosis, surgical treatment and prognosis. Piro­gov Russian Journal of Surgery. 2025;(6):104-111
Portopulmonary hype­rtension. Journal of Respiratory Medi­cine. 2025;(2):39-44
Diagnosis and treatment of ovarian cancer in pregnancy. Russian Bulletin of Obstetrician-Gynecologist. 2025;(3):27-33
Abstract:

Keywords:

depersonalization syndrom
clinical characteristics
treatment

Authors:

Aliev N.A.

Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare Department, Moscow, Russia

Aliev Z.N.

Close metadata

References:

  1. Akhapkina M.V.Psikhopatologiya i klinika depersonalizatsionnykh rasstroistv pri shizofrenii: Avtoref. dis. ... kand. med. nauk. M 1993; 22.
  2. Zhmurov V.A.Psikhopatologiya. M: Meditsinskaya kniga, Nizhnii Novgorod 2002; 668.
  3. Kafarov T.A.Dinamika rasstroistv samosoznaniya v klinike shizofrenii. Baku 1998; 26.
  4. Kafarov T.A.Psikhopatologiya samosoznaniya v patokineze shizofrenii: Avtoref. dis. ... d-ra med. nauk. Baku 2000; 285.
  5. Klinicheskaya psikhiatriya. Per. s angl. Glavnyi redaktor T.B. Dmitrieva M: GEOTAR 1998; 505.
  6. Myasishchev V.N.Soznanie kak edinstvo otrazheniya deistvitel'nosti i otnosheniyakh k nei cheloveka. Problemy soznaniya. M 1966; 126-132.
  7. Nosachev G.N.Endogennye depressii i depersonalizatsiya. M 1989.
  8. Nosachev G.N.Endogennye depressii: sistematika, psikhopatologiya, terapiya: Avtoref. dis. ... d-ra med. nauk. M 1991.
  9. Nosachev G.N., Baranov B.C.Znachenie narushenii samosoznaniya pri endogennykh psikhozakh dlya reabilitatsionnykh meropriyatii. Nevrologicheskii vestnik 1994; XXVI: 3-4: 24-28.
  10. Nuller Yu.L.Depressiya i depersonalizatsiya. L: Meditsina 1981; 207.
  11. Nuller Yu.L.Depersonalizatsiya: patogeneticheskie mekhanizmy i terapiya. KhIII s''ezd psikhiatrov Rossii 10-13.10.2000 g. Materialy. M 2000; 190.
  12. Nuller Yu.L., Mikhalenko I.N.Affektivnye psikhozy. L: Meditsina 1988; 264.
  13. Psikhiatriya. Natsional'noe rukovodstvo. Glavnye redaktory: T.B. Dmitrieva i dr. M: GEOTAR 2009; 1000.
  14. Semenov S.F.O klinicheskikh proyavleniyakh rasstroistva samosoznaniya. Problemy soznaniya. Materialy simpoziuma. M 1966; 240-247.
  15. Sergeev I.I., Basova A.L.Bredovaya depersonalizatsiya. M: Tsifrovichel 2009; 192.
  16. Smulevich A.B., Vorob'ev V.A.Depersonalizatsiya, kliniko-psikhopatologicheskie aspekty. Zhurn nevropatol i psikhiatr 1973; 8: 1242-1252.
  17. Snezhnevskii A.V.Obshchaya psikhopatologiya: Kurs lektsii. Valdai 1970; 178.
  18. Snezhnevskii A.V.Klinicheskaya psikhopatologiya V kn.: Rukovodstvo po psikhiatrii. M 1983; 1: 16-96.
  19. Shmar'yan A.S.K voprosu o psikhofiziologicheskikh zakonomernostyakh depersonalizatsii. Sovetskaya nevropatologiya, psikhiatriya i psikhogigiena 1934; 3: 6: 67-96.
  20. Shogam A.N.Problema soznaniya i psikhologicheskaya model' lichnosti. Problemy soznaniya. Materialy simpoziuma. M 1966; 195-210.
  21. Yaspers K.Obshchaya psikhopatologiya. Per. s nem. M: Praktika 1997; 1056.
  22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition, text revised. Washington, DC 2000.
  23. Anand A., Charney D.S., Oren D.A. et al.Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000; 57: 270-276.
  24. Black D.W., Wojcieszek J.Depersonalization syndrome induced by fluoxetine. Psychosomatics 1991; 32: 468-469.
  25. Bohus M.J., Landwehrmeyer G.V., Stiglmayr S.E. et al.Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J Clin Psychiatry 1999; 60: 598-603.
  26. Brauer R., Harrow M., Tucker G.J.Depersonalisation phenomena in psychiatric patients. Brit J Psychiatry 1970; 117: 509-515.
  27. British Medical Association and Royal Pharmaceutical Society of Great Britain British National Formulary. London: BMJ Books and Pharmaceutical Press 2004.
  28. Danel T., Leys D., Destee A.Anosognosia and depression. Neurology 1991; 41: 6: 951.
  29. Dugas L., Moutier F.La dépersonnalisation. Paris 1911; 223.
  30. Haug K.Depersonslisasion and verwandte Erscheinungen. Hand. Geisteskr. Hrsg. V.O. Bumke. Erganz. Berlin 1939; 1: 134-204.
  31. Hollander E., Liebowitz M.R., DeCaria C. et al.Treatment of depersonalization with serotonin reuptake blockers. J Clin Psychopharmacology 1990; 10: 200-203.
  32. Hunter E.C., Sierra M., David A.S.The epidemiology of depersonalisation and derealisation. A systematic review. Soc Psychiatry Psychiatr Epidemiol 2004; 39: l: 9-18.
  33. Medford N., Sierra M., Baker D., David A.S.Understanding and treating depersonalisation disorder. Adv Psychiatric Treatment 2005; 11: 92-100.
  34. Michal M., Beutel M.E., Grobe T.G.How often is the Depersonalization-Derealization Disorder (ICD-10: F48.1) diagnosed in the outpatient health-care service? Z Psychosom Med Psychother 2010; 56: 1: 74-83.
  35. Michal M., Wiltink J., Subic-Wrana C. et al.Prevalence, correlates, and predictors of depersonalization experiences in the German general population. J Nerv Ment Dis 2009; 197: 7: 499-506.
  36. Nuller Y.L.Depersonalisazion - symptoms, meaning, therapy. Acta Psychiatr Scand 1982; 66: 451-458.
  37. Nuller Y.L., Morozova M.G., Kushnir O.N., Hamper N.Effect of naloxone therapy on depersonalization: a pilot study. J Psychopharmacol 2001; 15: 93-95.
  38. Ratliff N.B., Kerski D.Depersonalization treated with fluoxetine (letter). Am J Psychiatry 1995; 152: 1689-1690.
  39. Sachdev P.Citalopram-Clonazepam combination for primary depersonalization disorder: a case report. Austr N Z J Psychiatry 2002; 36: 424-425.
  40. Sarkar J., Jones N., Sullivan G.A case of depersonalization-derealization syndrome during treatment with quetiapine. J Psychopharmacol 2001; 15: 209-211.
  41. Sierra M., Berrios G.E.A case of depersonalization. Hist Psychiatry 1996: 7: 451-461.
  42. Sierra M., Berrios G.E.The Cambridge Depersonalization Scale: a new instrument for the measurement of depersonalization. Psychiatry Res 2000; 93: 153-164.
  43. Sierra M., Phillips M.L., Ivin G. et al.A placebo-controlled crossover trial of lamotrigine in depersonalization disorder. J Psychopharmacology 2003; 17: 103-105.
  44. Sierra M., Baker D., Medford N. et al.Lamotrigine as an Add-on Treatment for Depersonalization Disorder: A Retrospective Study of 32 Cases. J Clin Neuropharmacol 2006; 29: 253-258.
  45. Sierra M.Depersonalization disorder: pharmacological approaches. Exp Rev Neurotherapeutics 2008; 8: 1: 19-26.
  46. Sierra M.Depersonalization: A New Look at a Neglected Syndrom. New York: Cambridge University Press 2009.
  47. Simeon D., Hollander E., Stein D.J. et al.Induction of depersonalization by the serotonin agonist meta-chlorophenylpiperazine. Psychiat Res 1995; 58: 161-164.
  48. Simeon D., Stein D.J., Hollander E.Treatment of depersonalization disorder with clomipramine. Biol Psychiat1998; 44: 302-303.
  49. Simeon D.Depersonalisation disorder: a contemporary overview. CNS Drugs 2004; 18: 6: 343-354.
  50. Stein M.B., Uhde T.W.Depersonalization disorder: effects of caffeine and response to pharmacotherapy. Biol Psychiat 1989; 26: 315-320.
  51. Strohle A., Kumpfel T., Sonntag A.Paroxetine for depersonalization associated with multiple sclerosis. Am J Psychiat 2000; 157: 150.
  52. Walsh S.L., Strain E.C., Abreu M.E. et al.Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berlin) 2001; 157: 151-162.
  53. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Geneva: WHO 1992.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.